ReviewPharmaceutics2023
Recent Progress of Lipid Nanoparticles-Based Lipophilic Drug Delivery: Focus on Surface Modifications.
Review in Pharmaceutics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
57 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Potential of the Nano-Encapsulation of Antioxidant Molecules in Wound Healing Applications: An Innovative Strategy to Enhance the Bio-Profile.Molecules (Basel, Switzerland) · 2025Pooled it
- Advances in Cubosome-Based Transdermal Delivery: Structural Design, Manufacturing, and Engineering Strategies.ACS omega · 2026Review
- Layer by Layer Engineered Lipid-Based Nanocarriers for Therapeutic Delivery and Next-Generation Design.Pharmaceutics · 2026Review
- Repositioning pentoxifylline via inhalable novasomes for pulmonary fibrosis: from statistical optimization to in-vivo evaluation.Drug delivery and translational research · 2026Article
- Single-ligand dual-targeting lipid nanoparticles for therapeutic mRNA delivery to glioblastoma across the blood-brain barrier.Journal of controlled release : official journal of the Controlled Release Society · 2026Article
- Contrast Agents for Enhanced Bioimaging: A Comprehensive Review.Chembiochem : a European journal of chemical biology · 2026Review
- Lipid nanocarriers as innovative strategies for hair regrowth.Discover nano · 2026Review
- Recent advances in lipid nanoparticles for cancer vaccine delivery: Challenges and future perspectives.International journal of pharmaceutics: X · 2026Review
- Coaxial Jet Mixing for Pharmaceutical Nanocarrier Production: Experimental Analysis and Mechanistic Modeling.Pharmaceutics · 2026Article
- Reengineering statin therapy to protect skeletal muscle: nanocarrier strategies for mitigating mitochondrial dysfunction and myotoxicity.Inflammation and regeneration · 2026Review
- Synergy between Antimicrobial Peptides and Lipid Nanoparticles for Skin Infection Control.ACS applied materials & interfaces · 2026Review
- Nanotechnology for reproductive healthcare: a comprehensive review.Journal of nanobiotechnology · 2026Review
- Nanocarrier-mediated CRISPR-Cas delivery: a novel approach against antibiotic-resistant superbugs.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2026Review
- From nanoscale to clinic: The growing impact of nanotechnology in translational drug delivery.ADMET & DMPK · 2026Review
- Exploring NanoherbalIranian journal of medical sciences · 2025Article
- Structure-centered design of lipid-based nanocarriers to overcome biological barriers.Materials today. Bio · 2025Review
- Recent advances in potential drug nanocarriers for CNS disorders: a review.Biomedical engineering online · 2025Review
- Polymer- and Lipid-Based Nanostructures for Wound Healing with Barrier-Resolved Design.Pharmaceutics · 2025Review
- Targeted Nanoparticles for Drug Delivery Across the Blood-Brain Barrier in Early and Late Stages of Alzheimer's Disease: A Review.Molecular neurobiology · 2025Review
- Oleosome Delivery Systems: Enhancing Stability and Therapeutic Potential of Natural Products and Xenobiotics.Pharmaceutics · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Numerous drugs have emerged to treat various diseases, such as COVID-19, cancer, and protect human health. Approximately 40% of them are lipophilic and are used for treating diseases through various delivery routes, including skin absorption, oral administration, and injection. However, as lipophilic drugs have a low solubility in the human body, drug delivery systems (DDSs) are being actively developed to increase drug bioavailability. Liposomes, micro-sponges, and polymer-based nanoparticles have been proposed as DDS carriers for lipophilic drugs. However, their instability, cytotoxicity, and lack of targeting ability limit their commercialization. Lipid nanoparticles (LNPs) have fewer side effects, excellent biocompatibility, and high physical stability. LNPs are considered efficient vehicles of lipophilic drugs owing to their lipid-based internal structure. In addition, recent LNP studies suggest that the bioavailability of LNP can be increased through surface modifications, such as PEGylation, chitosan, and surfactant protein coating. Thus, their combinations have an abundant utilization potential in the fields of DDSs for carrying lipophilic drugs. In this review, the functions and efficiencies of various types of LNPs and surface modifications developed to optimize lipophilic drug delivery are discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.